| Follicular lymphoma international prognostic index P Solal-Céligny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, ... Blood 104 (5), 1258-1265, 2004 | 2150 | 2004 |
| Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ... Annals of oncology 26, v116-v125, 2015 | 1087 | 2015 |
| Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage … A Gallamini, M Hutchings, L Rigacci, L Specht, F Merli, M Hansen, C Patti, ... Journal of clinical oncology 25 (24), 3746-3752, 2007 | 1031 | 2007 |
| Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project M Federico, M Bellei, L Marcheselli, S Luminari, A Lopez-Guillermo, ... Journal of Clinical Oncology 27 (27), 4555-4562, 2009 | 875 | 2009 |
| Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study A Gallamini, C Stelitano, R Calvi, M Bellei, D Mattei, U Vitolo, F Morabito, ... Blood 103 (7), 2474-2479, 2004 | 769 | 2004 |
| Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆ M Dreyling, M Ghielmini, S Rule, G Salles, M Ladetto, SH Tonino, ... Annals of Oncology 32 (3), 298-308, 2021 | 721* | 2021 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 694 | 2019 |
| Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ... Journal of Clinical Oncology 21 (1), 20-27, 2003 | 574 | 2003 |
| Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma F Morschhauser, J Radford, A Van Hoof, U Vitolo, P Soubeyran, H Tilly, ... Journal of Clinical Oncology 26 (32), 5156-5164, 2008 | 531 | 2008 |
| ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned S Viviani, PL Zinzani, A Rambaldi, E Brusamolino, A Levis, V Bonfante, ... New England Journal of Medicine 365 (3), 203-212, 2011 | 506 | 2011 |
| Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma U Vitolo, M Trněný, D Belada, JM Burke, AM Carella, N Chua, ... Journal of clinical oncology 35 (31), 3529-3537, 2017 | 431 | 2017 |
| The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease A Gallamini, L Rigacci, F Merli, L Nassi, A Bosi, I Capodanno, S Luminari, ... haematologica 91 (4), 475-481, 2006 | 370 | 2006 |
| Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma M Esteller, G Gaidano, SN Goodman, V Zagonel, D Capello, B Botto, ... Journal of the National Cancer Institute 94 (1), 26-32, 2002 | 359 | 2002 |
| R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana … M Federico, S Luminari, A Dondi, A Tucci, U Vitolo, L Rigacci, ... Journal of Clinical Oncology 31 (12), 1506-1513, 2013 | 318 | 2013 |
| Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis … M Ladetto, F De Marco, F Benedetti, U Vitolo, C Patti, A Rambaldi, ... Blood, The Journal of the American Society of Hematology 111 (8), 4004-4013, 2008 | 295 | 2008 |
| Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP P Pregno, A Chiappella, M Bellò, B Botto, S Ferrero, S Franceschetti, ... Blood, The Journal of the American Society of Hematology 119 (9), 2066-2073, 2012 | 285 | 2012 |
| Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the … E Zucca, A Conconi, D Laszlo, A López-Guillermo, R Bouabdallah, ... Journal of Clinical Oncology 31 (5), 565-572, 2013 | 274 | 2013 |
| First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an … U Vitolo, A Chiappella, AJM Ferreri, M Martelli, I Baldi, M Balzarotti, ... Journal of Clinical Oncology 29 (20), 2766-2772, 2011 | 270 | 2011 |
| Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, ... Annals of Oncology 28 (9), 2169-2178, 2017 | 263 | 2017 |
| Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia D Capello, U Vitolo, L Pasqualucci, S Quattrone, G Migliaretti, L Fassone, ... Blood, The Journal of the American Society of Hematology 95 (2), 651-659, 2000 | 262 | 2000 |
